Two Drugs Are No More Effective Than One to Treat Common Kidney Disease
Bethesda, MD - Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health (NIH). One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment.
The results of the HALT-PKD Clinical Trials Network studies will be published online today in two papers in the New England Journal of Medicine to coincide with presentation at the American Society of Nephrology annual meeting.
“Enlarged cysts in kidneys can lead to reduced kidney function and eventually kidney failure, where the only treatment is dialysis or transplantation,” said study author Michael Flessner, M.D., Ph.D., a program director at the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases, which funded the trial. “The HALT-PKD findings show that people with polycystic kidney disease do not need to take both of the drugs studied to slow their rate of kidney cyst growth and decline in kidney function.”
The HALT-PKD trial enrolled volunteers to test whether a combination of commonly used FDA-approved drugs, lisinopril and telmisartan, could shrink kidney cysts and therefore slow progression of ADPKD, a genetic disorder characterized by growth of fluid-filled cysts in the kidneys. Within the trial, one study examined 558 people with early-stage ADPKD and relatively healthy kidneys. The other study treated 486 people with more advanced disease and decreased kidney function. In each study, half of participants were randomly assigned to receive lisinopril and telmisartan, while the other half received lisinopril plus a placebo. In both studies, adding the second drug did not change kidney function or rate of increase in kidney cyst size. Continue>
Page | 1 2
Posted in: Pharma | June 21, 2013
Posted in: Pharma | July 31, 2013
Posted in: Pharma | August 19, 2013